Circulating adiponectin levels and risk of endometrial cancer: the prospective Nurses' Health Study.
OBJECTIVE
Adiponectin, a protein secreted by adipose cells, is inversely associated with endometrial cancer. Our objective was to assess prediagnostic adiponectin levels in relation to risk of endometrial cancer.


METHODS
This was a prospective nested case-control study within the Nurses' Health Study with 146 cases and 377 controls. Adiponectin was measured using enzyme-linked immunosorbent assay. Logistic regression analyses were performed adjusting for known endometrial cancer risk factors.


RESULTS
Mean age at diagnosis was 64.6 years. Mean interval between blood draw and diagnosis was 7.4 years (range, 2-13). There was no difference in median adiponectin (cases 12.9 vs controls 12.9 μg/mL; P = .97). Adiponectin >15 μg/mL was not associated with endometrial cancer risk (relative risk = 0.86; 95% confidence interval, 0.53-1.39; P = .48), even among postmenopausal women (odds ratio, 0.66; 95% confidence interval, 0.29-1.5). Results did not vary by time from blood draw to diagnosis (P for heterogeneity = .18).


CONCLUSIONS
Prediagnostic adiponectin was not predictive of endometrial cancer risk. Further study will better define the relationship between adiponectin and endometrial cancer.
Department of Gynecologic Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA. psoliman@mdanderson.org
Pamela T
PT
Soliman
Xiaohui
X
Cui
Qian
Q
Zhang
Susan E
SE
Hankinson
Karen H
KH
Lu
D052242:Adiponectin / Q000097:blood*; D000368:Aged; D015992:Body Mass Index; D018269:Carcinoma, Endometrioid / Q000097:blood*; D016022:Case-Control Studies; D016009:Chi-Square Distribution; D016889:Endometrial Neoplasms / Q000097:blood*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006306:Health Surveys; D006801:Humans; D016015:Logistic Models; D008875:Middle Aged; D016017:Odds Ratio; D011446:Prospective Studies; D012306:Risk
D052242:Adiponectin